Ignite Creation Date:
2025-12-24 @ 6:47 PM
Ignite Modification Date:
2026-03-03 @ 6:05 PM
Study NCT ID:
NCT01753557
Status:
COMPLETED
Last Update Posted:
2016-10-03
First Post:
2012-12-13
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C
Sponsor:
Tanabe Pharma Corporation
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-12
Start Date Type:
None
Primary Completion Date:
2014-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-11
Completion Date Type:
ACTUAL
First Submit Date:
2012-12-13
First Submit QC Date:
None
Study First Post Date:
2012-12-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-06-14
Results First Submit QC Date:
None
Results First Post Date:
2016-10-03
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2016-08-09
Last Update Post Date:
2016-10-03
Last Update Post Date Type:
ESTIMATED